7 research outputs found
Dose escalation efficiency parameters of first-in-human phase I trials of molecularly targeted agents according to the dose escalation method used.
<p>3+3â=ââ3+3â dose escalation method; ATDâ=âAccelerated titration design; mCRMâ=âModified continual reassessment method; PGDEâ=âPharmacologically guided dose escalation; NSâ=âNot specified; MTDâ=âMaximum tolerated dose; NAâ=âNot applicable.</p
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s40487-016-0027-x">https://link.springer.com/article/10.1007/s40487-016-0027-x</a></p><p></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/ĂąÂÂmailto:[email protected]ĂąÂÂ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>âą Slide decks</p>
<p>âą Videos and animations</p>
<p>âą Audio abstracts</p>
<p>âą Audio slides</p
Distribution of the number of mutations according to mutational signatures in HR+/HER2â metastatic and primary (TCGA) breast tumors.
<p>Distribution of the number of mutations according to mutational signatures in HR+/HER2â metastatic and primary (TCGA) breast tumors.</p
Somatic mutations of genes <i>TSC1</i>, <i>TSC2</i>, <i>ERBB4</i>, and <i>NOTCH3</i> in mBC (from cBioPortal).
<p>Green dots represent missense mutations, while black dots represent truncating mutations.</p
Driver gene mutations in metastatic breast cancers.
<p>The top panel shows the synonymous and nonsynonymous mutation rates (number of mutations) per patient according to the molecular subtype of the metastasis. HR, hormone receptor; ND, not determined. The bottom panel shows the significantly mutated genes according to MutSig analysis at FDR < 0.1. Amplifications and deletions correspond to the thresholded values from the Gistic2 output (respectively +2 and â2 values).</p
Distribution of the number of mutations according to mutational signatures in HR+/HER2â metastatic and primary (TCGA) breast tumors.
<p>Distribution of the number of mutations according to mutational signatures in HR+/HER2â metastatic and primary (TCGA) breast tumors.</p
COSMIC mutational signature contribution in mBC.
<p>DNA DSBR, DNA double-strand break-repair by homologous recombination; DNA MMR, DNA mismatch repair.</p